|
| Case 1 | Case 2 |
|
Age (years)/gender | 77/male | 47/male |
|
Possible/probable exposure Date/timing of exposure | Cape Verde From 1944 to 1965 | Guinea-Bissau From several years to months before |
|
Risk factors for infection and HIS/DS (3, 7, 8) |
Alcoholism | No | No |
HIV-infection | No | No |
HTLV-1 infection | No | No |
Hematologic malignancy | No | No |
Solid organ transplant | No | No |
Immunosuppressive therapy | Yes | Yes |
Type | Corticosteroid (dexamethasone) | Corticosteroid (dexamethasone) |
Cumulative dose equivalence (prednisone) until HIS/DS | 1426 mg | 3067 mg |
Time from beginning immunosuppression to HIS/DS | 32 days | 37 days |
|
Other comorbidities | Hypertension Dyslipidaemia | Colon adenocarcinoma in remission Chronic kidney disease Previous hepatitis B |
|
Confirmed organ/system involvement during DS | Gastrointestinal Pulmonary Urinary Central nervous system | Gastrointestinal Pulmonary Urinary |
|
Strongyloidiasis therapy given | Ivermectin 200 μg/kg id (oral, NGT) Albendazole 400 mg bid (oral, NGT) | Ivermectin 200 μg/kg id (oral, NGT) 10 days Ivermectin 200 μg/kg id (subcutaneous) 5 days Albendazole 400 mg bid (oral, NGT) 15 days |
|
Complications | (i) Bacteraemia due to K. pneumoniae (ii) Ventilator-associated pneumonia due to KPC-producing K. pneumoniae (iii) Meningitis to E. faecium | (i) CMV reactivation with possible colitis (ii) Pulmonary aspergillosis (iii) Bacteraemia due to K. pneumoniae (iv) Bloodstream infection due to C. albicans (v) HSV-1/VZV oral mucositis (vi) HBV reactivation |
|
Outcome and time to outcome (after diagnosis) | Cure of strongyloidiasis in 4 weeks Death after 61 days (due to hospital-acquired SARS-CoV-2 pneumonia) | No cure for strongyloidiasis Death after 15 days |
|